Erschienen in:
09.03.2021 | Letter to the Editor
Detecting DPD deficiency: when perfect is the enemy of good
verfasst von:
Joseph Ciccolini, Gérard Milano, Henk-Jan Guchelaar
Erschienen in:
Cancer Chemotherapy and Pharmacology
|
Ausgabe 5/2021
Einloggen, um Zugang zu erhalten
Excerpt
DPD deficiency makes patients prone to severe and sometimes even life threatening or fatal toxicities upon fluoropyrimidine drug administration (i.e. 5-FU and capecitabine). In their interesting paper “Comparison of a thymine challenge test and endogenous uracil–dihydrouracil levels for assessment of fluoropyrimidine toxicity risk”, Burns et al. present a new strategy (“THY challenge test”) to detect patients with impaired DPD activity [
1]. Although tested on a limited number of patients and requiring adjustment on patient’s renal function, the presented THY challenge test could be an alternative to canonical U or UH2/U monitoring in plasma to detect on a functional basis for patients with severe toxicities upon 5-FU administration. …